What Is Ozempic? A Plain-Language Explainer

Published May 25, 2026Updated May 27, 2026Last reviewed May 25, 2026

For the broader cluster context, see the semaglutide vs Ozempic and Wegovy comparison hub.

Author: HealthRX Editorial Team Medically reviewed by: Dr. Mark Halpern, MD (Internal Medicine, Obesity Medicine) Last clinical review: May 2026

Compounded semaglutide is not FDA-approved. This article is patient education and does not replace consultation with a licensed clinician.

Last March, a woman named Rachel in Austin told her endocrinologist she wanted "the Ozempic." She'd seen it on TikTok, heard about it at her daughter's soccer game, and read three conflicting articles about it before breakfast. Her doctor, Dr. Patel at a midtown internal medicine practice, spent 40 minutes explaining that what Rachel actually wanted might not be Ozempic at all. "She had a BMI of 34, no diabetes, and good insurance that wouldn't cover Ozempic off-label," Patel told me. "What she needed was a conversation about semaglutide, the molecule, not the brand. Those are two different things, and the marketing has completely blurred the line."

That confusion is everywhere. And it's worth untangling carefully.

This guide sits inside the broader Compounded Semaglutide vs Ozempic and Wegovy cluster, which is part of the compounded semaglutide pillar guide.

The Molecule vs. the Brand Name

Here's the thing most people get wrong right out of the gate: "Ozempic" is not a drug. It's a brand name applied to a drug. The drug is semaglutide, a GLP-1 receptor agonist engineered to mimic a gut hormone your body already makes, just with a much longer shelf life in circulation.

Native GLP-1, the hormone your intestines release after a meal, survives in your bloodstream for about two minutes. That's useless for therapy. Semaglutide was designed to resist the enzymes that chew up native GLP-1 and to hitch a ride on albumin (a protein in your blood), which extends its effective half-life to roughly a week. That's why it's a once-weekly injection.

Novo Nordisk manufactures two branded versions:

Ozempic: FDA-approved for type 2 diabetes. Available in pre-filled pen doses of 0.25 mg (starting/tolerability dose), 0.5 mg, 1.0 mg, and 2.0 mg.
Wegovy: FDA-approved for chronic weight management in eligible patients. Same molecule, higher labeled maintenance dose of 2.4 mg.

Same active ingredient. Different label, different dose ceiling, different insurance codes.

Compounded semaglutide is a third option. It's prepared by a licensed compounding pharmacy under a patient-specific clinician prescription. It uses the same active ingredient. It is not FDA-approved. And it has not been tested in randomized trials at the same scale as the branded products. This distinction matters, and we'll come back to it.

What the Clinical Trials Actually Show

The evidence base for semaglutide, the molecule, is extensive. It comes from branded-product trials, which is important to acknowledge up front: when we cite these numbers for compounded semaglutide patients, we're extrapolating from the molecule, not from the specific compounded preparation.

The STEP-1 trial tested 2.4 mg weekly semaglutide against placebo over 68 weeks and reported mean weight loss of 14.9 percent from baseline in the active arm. That's a big number. It moved the field.

STEP-3 layered a structured lifestyle intervention (intensive behavioral therapy, meal replacements) on top of the same drug protocol and produced even greater mean weight loss. The read: the medication isn't doing everything alone. Lifestyle is additive, not decorative.

STEP-4 is the one patients tend not to hear about, and it's arguably the most important. Participants who switched from active semaglutide to placebo at week 20 experienced partial weight regain over the following 48 weeks. The chronic biology of weight regulation doesn't simply reset. Think of it like blood pressure medication: stop taking lisinopril, and your blood pressure trends back up. Obesity treatment works the same way. This isn't a "course" of medication. It's management of a chronic condition.

On the cardiovascular side, SUSTAIN-6 and LEADER anchored the safety profile for the GLP-1 class. And SELECT, completed in 2023, reported a 20 percent relative reduction in major adverse cardiovascular events with semaglutide 2.4 mg in patients with established cardiovascular disease and overweight or obesity without diabetes. That trial changed the conversation about who should be on these medications and why.

Where People Get Confused

The most persistent mistake in patient-facing content (and there's a lot of bad content out there) is treating compounded semaglutide as either identical to or categorically inferior to branded Ozempic/Wegovy. Neither framing holds up.

The active ingredient is the same molecule. The regulatory pathway is different. The manufacturing oversight is different. The supply chain is different. Compounding pharmacies operate under a separate framework (503A or 503B), with different inspection protocols and different requirements than what Novo Nordisk's manufacturing facilities face.

This doesn't automatically make compounded semaglutide "worse." It does mean the conversation with your prescriber should be longer and more specific than the marketing copy on any telehealth website suggests. My honest opinion: if someone is selling you semaglutide (branded or compounded) without a real clinical conversation, that's a red flag regardless of which version they're pushing.

A few other misconceptions that come up constantly:

"Side effect intensity means it's working." No. The STEP-1 and STEP-3 data don't support this. Patients with mild GI side effects and patients with significant nausea both achieved meaningful weight loss. Suffering more doesn't mean losing more.

"The medication does all the work." STEP-3's superior results compared to STEP-1 say otherwise. The drug suppresses appetite and slows gastric emptying. What you eat during that window of reduced intake still matters, possibly more than before, because every calorie carries more nutritional weight when total intake drops by 30 or 40 percent.

"Once I lose the weight, I'm done." See STEP-4 above. The biology of weight regulation is persistent. Planning for a long-term strategy, whether pharmacologic or otherwise, is not optional.

Three Things That Actually Separate Branded from Compounded

Strip away the noise and three practical factors drive the decision between branded and compounded semaglutide:

1. Access and cost. Branded Ozempic or Wegovy requires either insurance coverage (which is inconsistent, especially for weight management indications) or out-of-pocket payment near list price, which can run well over $1,000 per month. Compounded preparations operate under a different cost structure but without FDA approval.

2. Dose flexibility. Pre-filled pens come in fixed increments. Compounded preparations can be titrated in smaller steps, which some clinicians prefer for patients who are particularly sensitive to GI side effects or who need non-standard dosing.

3. Clinical context. A patient with type 2 diabetes and cardiovascular risk factors has a different clinical rationale (and potentially different insurance pathways) than someone seeking treatment for weight management without diabetes. The "right" product depends on who you are medically, not on which brand has the better Instagram ad.

What Actually Produces Good Outcomes

I'll say something that might sound boring but is true: the program matters more than the product. A clinician who monitors your labs, adjusts your dose based on tolerability, checks in between refills, and has a real plan for nutritional support will produce better results than a flashy website selling auto-refills with minimal oversight.

The molecule works. The STEP data are clear on that. But the molecule in the hands of a responsive clinical team works better than the molecule shipped to your door with a PDF attachment.

Compounded semaglutide is prepared by a licensed compounding pharmacy under a clinician prescription. It uses the same active ingredient as Wegovy and Ozempic. It is not FDA-approved. The clinical evidence base for the molecule itself comes from the branded-product trials. Individual response varies. The trial means describe averages, not your specific outcome.

Adjacent Reading

Where This Fits

This article is part of the Compounded Semaglutide vs Ozempic and Wegovy cluster. For a broader treatment of the molecule, the regulatory pathway, the 503A and 503B compounding framework, and the clinical evidence base, the compounded semaglutide pillar guide is the primary reference on this site.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

Compounded semaglutide uses the same active ingredient, semaglutide. It is prepared by a licensed compounding pharmacy under a clinician prescription and is not FDA-approved. Wegovy and Ozempic are FDA-approved branded products manufactured by Novo Nordisk. Same molecule, different regulatory status and manufacturing oversight.

What evidence applies across these forms?

The clinical trial evidence for semaglutide as a molecule comes from the SUSTAIN, STEP, and SELECT programs, all conducted with the branded products. Compounded preparations have not undergone equivalent randomized controlled trials. The molecular mechanism is the same; the evidence trail is specific to the branded versions.

Can patients switch between forms?

Switching between compounded and branded semaglutide is a clinical decision that depends on dose, tolerability, and access. It should be supervised by your prescriber, not done independently.

Why is Ozempic prescribed off-label for weight loss?

Ozempic's FDA approval is for type 2 diabetes, not weight management. Some clinicians prescribe it off-label for weight loss when Wegovy (the weight-management-indicated version) is unavailable or inaccessible. Off-label prescribing is legal and common in medicine, but insurance coverage for off-label use is unpredictable.

How long does treatment typically last?

Based on STEP-4 data showing partial weight regain after discontinuation, most obesity medicine specialists now frame semaglutide therapy as long-term or indefinite, similar to how blood pressure or cholesterol medications are prescribed. The duration depends on individual clinical response and goals, discussed with your prescriber.

Compliance and Authorship

This article references the STEP-1, STEP-3, STEP-4, SUSTAIN, SELECT, and LEADER clinical trial programs where appropriate. It is intended as patient education and does not replace consultation with a licensed clinician.